The combination of CC-122, an investigational pleiotropic pathway modulator, and the second-generation anti-CD20 antibody obinutuzumab induced strong responses in patients with relapsed or refractory follicular lymphoma.
Jean-Marie Michot, MD, a medical internist with Institut de Cancérologie Gustave Roussy in Villejuif, France, presented results from the phase I CC-122- NHL-001 study at the 2018 International Congress on Targeted Anticancer Therapies held in Paris. He said these results establish the combination as a new chemotherapy-free treatment regimen for patients with relapsed/ refractory FL.
“The CC-122 and obinutuzumab combination is consistent with the tolerability profile of either therapy alone, with no unexpected toxicities,” he said. “The combination demonstrates similar activity in high-risk and standard-risk patients [with FL].”
Michot called FL the most important histology treated in this study of B-cell non-Hodgkin lymphomas. The objective response rate (ORR) was 77% for patients with FL or marginal zone lymphoma (MZL). Twelve patients (40%) with FL had a complete response (CR) and 11 (37%) had a partial response (PR); the 1 patient with MZL achieved a PR. Two additional patients (7%) with FL had stable disease (TABLE).
Median progression-free survival (PFS) was 16.6 months in the FL or MZL group (95% CI, 5.4-not reached), with a 6-month PFS of 71.9% (95% CI, 49.5%-85.7%) and a median duration of response of 19.4 months (95% CI, 8.4-not reached).
The CC-122/obinutuzumab combination also showed strong efficacy in high-risk patients with FL, defined as relapse within 2 years of initial diagnosis (early relapse) or refractory to rituximab alone or in combination, and refractory to an alkylating agent (double refractory). The ORR was 75% in these high-risk patients (n = 16), including 6 CRs (38%) and 6 PRs (38%).
In comparison, the ORR was 77% in nonhigh-risk patients with FL, including 6 CRs (46%) and 4 PRs (31%).
The median PFS was 21.2 months (95% CI, 3.7-not reached) in the high-risk group compared with 16.6 months (95% CI, 5.4-16.6) in the nonhigh-risk group. Six-month PFS was 64.2% (95% CI, 33.6%-83.5%) in the high-risk group compared with 79.5% (95% CI, 39.3%-94.5%) in the non–high-risk group. Median duration of response favored the high-risk group at 19.4 versus 8.4 months.
“This is quite clearly a limited number of patients, but clearly we can see that CC-122 and obinutuzumab is effective in patients with high-risk and standard-risk follicular lymphoma,” Michot said.
CC-122-NHL-001 was a 2-stage study of patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) or indolent non-Hodgkin lymphoma. Eligible patients had histologically or cytologically confirmed DLBCL; grade 1, 2, or 3a FL; or MZL. All patients were CD20-positive and had a measurable lesion ≥1.5 cm.
Stage 1 was a classic 3+3 structure dose-establishing study, which established 3.0 mg of CC-122 as the treatment dose for stage 2. CC-122 was administered on days 1 through 5 every 7 days in 28-day cycles in phase 2. Obinutuzumab was administered at 1000 mg on days 2, 8, and 15 during the first cycle and on each day 1 of cycles 2 through 8.
Two patients experienced a dose-limiting toxicity in stage 1; 1 patient treated with 3.0 mg of CC-122 had grade 4 neutropenia, and 1 treated with 4.0 mg of CC-122 had a fatal tumor flare reaction.
The majority of patients had FL (59%). Nineteen patients (39%) had DLBCL and 1 (2%) was diagnosed with MZL.
The median patient age was 60 years (range, 26-83); 33% of patients were aged >65 years. Thirty-two patients (65%) were male.
The median number of prior systemic therapies was 3 (range, 1-11). Twenty-five patients (51%) were refractory to rituximab (Rituxan) and 19 (39%) had undergone prior stem cell transplant.
Ten patients (20%) had positive bone marrow involvement and 5 (10%) had bulky disease.
Most patients (78%) had stage III/IV disease. Thirty patients (61%) had an ECOG performance status of 0 and 19 (39%) had a score of 1.
In the entire cohort (n = 49), the ORR was 65% with 14 CRs (29%) and 18 PRs (37%) on the combination. The ORR was 47% for patients with DLBCL, with 2 CRs (11%) and 7 PRs (37%).
Overall, the median PFS was 13.8 months (95% CI, 3.8-21.2) with a 6-month PFS of 59.5% (95% CI, 42.7%-72.8%) and a median duration of response of 10.2 months (95% CI, 8.4-not reached). Median PFS in the DLBCL group was 4.7 months, with a 6-month PFS of 40.0% (95% CI, 15.9%-63.3%) and a median duration of response of 10.2 months (95% CI, 1.8-10.2). Michot said that most responders maintained response beyond 12 months.
All patients were included in the safety analysis. The most common (≥20%) any-grade adverse events (AEs) were neutropenia (65%), thrombocytopenia (39%), diarrhea (29%), pyrexia (27%), and cough (22%).
The most common (≥5%) grade 3/4 AEs were neutropenia (55%), thrombocytopenia (22%), increased alanine aminotransferase (6%), and febrile neutropenia (6%).
Phase 2 of the study is ongoing and focusing on patients with FL who are relapsed/refractory and either lenalidomide (Revlimid)- naïve or lenalidomide-exposed.
Reference:
Michot JM, Bouabdallah R, Doorduijn JK, et al. CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Presented at: 2018 Targeted Anticancer Therapies; March 5-7, 2018; Paris, France. Abstract 480.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More